Lisa Cook sues Trump over firing attempt, emergency hearing set
Vaxart, Inc. (OTCQX:OTC:VXRT), a biotech company with a market capitalization of $81.77 million, held a virtual stockholder fireside chat with its management on Wednesday. According to a statement in a press release, the company has furnished a transcript of the event as an exhibit to its latest SEC filing. InvestingPro analysis shows the stock has faced significant headwinds, declining nearly 50% over the past six months, though analysts maintain price targets between $2-4.
The filing, submitted Thursday, indicates that the information provided in the transcript is not considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. The transcript was made available as Exhibit 99.1 in the report.
Vaxart is incorporated in Delaware and is based in South San Francisco, California. The company’s common stock is quoted on the OTCQX Best Market under the symbol VXRT.
No additional financial statements or material new disclosures were included in the filing beyond the availability of the fireside chat transcript. The information in this article is based on details from a press release statement and the related SEC filing.
In other recent news, Vaxart Inc. reported a notable increase in its Q2 2025 revenue, reaching $39.7 million, primarily due to a contract with the Biomedical Advanced Research and Development Authority (BARDA). Despite the revenue boost, the company posted an earnings per share (EPS) loss of $0.07, which was an improvement over the anticipated loss of $0.09. These financial results have been a focal point for investors assessing the company’s performance. Additionally, Vaxart announced plans to host a virtual stockholder fireside chat to discuss a proposed reverse stock split aimed at regaining compliance with Nasdaq listing requirements. This proposal has received backing from prominent proxy advisory firms, Institutional Shareholder Services and Glass Lewis (JO:LEWJ), who have recommended that stockholders support the initiative. These developments come as Vaxart continues to navigate its financial strategy and investor relations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.